Indications for Neoadjuvant, Adjuvant, and Palliative Chemotherapy in the Treatment of Biliary Tract Cancers

Surgical Oncology Clinics of North America

Volumn 18, Issue 2, 2009, Pages 361-379

  Huitzil Melendez, Fidel David ^a   O'Reilly, Eileen M ^a,b   Duffy, Austin ^a   Abou Alfa, Ghassan K ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant therapy; Biliary tract cancers; Chemotherapy; Cholangiocarcinoma; Gallbladder cancer; Regional chemotherapy; Targeted agents

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN C; OXALIPLATIN; SORAFENIB;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; AREA UNDER THE CURVE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GALLBLADDER CANCER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; INFECTION; LETHARGY; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER CANCER; META ANALYSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATHOGENESIS; PROGNOSIS; RASH; REVIEW; SEPSIS; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION;

BILIARY TRACT NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PALLIATIVE CARE;

EID: 62549102024     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.12.006     Document Type: Review

References (38)

1. In: Ries L.A.G., Melbert D., Krapcho M., et al. (Eds). SEER cancer statistics review (2005), National Cancer Institute, Bethesda (MD)
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 6 (2001) 1353-1357
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
4. Jarnagin W.R., Ruo L., Little S.A., et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98 8 (2003) 1689-1700
5. Fong Y., Blumgart L.H., Lin E., et al. Outcome of treatment for distal bile duct cancer. Br J Surg 83 12 (1996) 1712-1715
6. Endo I., Gonen M., Yopp A.C., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248 1 (2008) 84-96
7. Eckel F., and Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96 6 (2007) 896-902
8. Jarnagin W.R., Klimstra D.S., Hezel M., et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24 7 (2006) 1152-1160
9. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7 6 (1996) 593-600
10. Ducreux M., Van Cutsem E., Van Laethem J.L., et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 41 3 (2005) 398-403
11. Valle JW, Wasan H, Johnson P, et al. Gemcitabine, alone or in combination with cisplatin, in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumors: a multicentre randomised phase II study. In 2006 Gastrointestinal Cancers Symposium. San Francisco (CA) 2006.
12. Kornek G.V., Schuell B., Laengle F., et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15 3 (2004) 478-483
13. Rao S., Cunningham D., Hawkins R.E., et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 92 9 (2005) 1650-1654
14. Ducreux M., Rougier P., Fandi A., et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9 6 (1998) 653-656
15. Taieb J., Mitry E., Boige V., et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13 8 (2002) 1192-1196
16. Sanz-Altamira P.M., Ferrante K., Jenkins R.L., et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82 12 (1998) 2321-2325
17. Nehls O., Klump B., Arkenau H.T., et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 87 7 (2002) 702-704
18. Lim J.Y., Jeung H.C., Mun H.S., et al. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Anticancer Drugs 19 6 (2008) 631-635
19. Nehls O., Oettle H., Hartmann J.T., et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98 2 (2008) 309-315
20. Carraro S., Servienti P.J., Bruno M.F., et al. Gemcitabine and cisplatin in locally advanced or metastatic gallbladder and bile duct adenocarcinomas. Proc Am Soc Clin Oncol 20 (2001) [abstract 2333]
21. Malik I.A., Aziz Z., Zaidi S.H., et al. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 26 2 (2003) 174-177
22. Doval D.C., Sekhon J.S., Gupta S.K., et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90 8 (2004) 1516-1520
23. Thongprasert S., Napapan S., Charoentum C., et al. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16 2 (2005) 279-281
24. Lee J., Kim T.Y., Lee M.A., et al. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 61 1 (2008) 47-52
25. Julka P.K., Puri T., and Rath G.K. A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int 5 1 (2006) 110-114
26. Suresh R., Picus J., Sorscher S., et al. Gemcitabine and carboplatin in the treatment of metastatic cholangiocarcinoma and gallbladder cancer. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (2007) (June 20 Supplement) [abstract 15102]
27. Andre T., Tournigand C., Rosmorduc O., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15 9 (2004) 1339-1343
28. Harder J., Riecken B., Kummer O., et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 95 7 (2006) 848-852
29. Knox J.J., Hedley D., Oza A., et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 15 5 (2004) 770-774
30. Alberts S.R., Al-Khatib H., Mahoney M.R., et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103 1 (2005) 111-118
31. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23 10 (2005) 2332-2338
32. Cho J.Y., Paik Y.H., Chang Y.S., et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104 12 (2005) 2753-2758
33. Iyer R.V., Gibbs J., Kuvshinoff B., et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 14 11 (2007) 3202-3209
34. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24 19 (2006) 3069-3074
35. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
36. El-Khoueiry A.B., Rankin C., Lenz H.J., et al. SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (2007) [abstract 4639]
37. Jarnagin W.R., Schwartz L.H., Gultekin D.H., et al. Hepatic arterial infusional (HAI) therapy in patients with unresectable primary liver cancer: use of dynamic contrast enhanced MRI to evaluate response. J Clin Oncol 26 Suppl (2008) [abstract 4597]
38. Takada T., Amano H., Yasuda H., et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 8 (2002) 1685-1695